HUP0302093A3 - Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy - Google Patents

Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy

Info

Publication number
HUP0302093A3
HUP0302093A3 HU0302093A HUP0302093A HUP0302093A3 HU P0302093 A3 HUP0302093 A3 HU P0302093A3 HU 0302093 A HU0302093 A HU 0302093A HU P0302093 A HUP0302093 A HU P0302093A HU P0302093 A3 HUP0302093 A3 HU P0302093A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
replacement therapy
hormone replacement
medroxyprogesterone acetate
conjugated estrogens
Prior art date
Application number
HU0302093A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26886279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302093(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HUP0302093A2 publication Critical patent/HUP0302093A2/hu
Publication of HUP0302093A3 publication Critical patent/HUP0302093A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
HU0302093A 2000-03-20 2001-03-16 Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy HUP0302093A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19063000P 2000-03-20 2000-03-20
US26860701P 2001-02-14 2001-02-14
PCT/US2001/040302 WO2001070208A2 (en) 2000-03-20 2001-03-16 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate

Publications (2)

Publication Number Publication Date
HUP0302093A2 HUP0302093A2 (hu) 2003-10-28
HUP0302093A3 true HUP0302093A3 (en) 2010-03-29

Family

ID=26886279

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302093A HUP0302093A3 (en) 2000-03-20 2001-03-16 Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy

Country Status (30)

Country Link
US (2) US20010034340A1 (hu)
EP (1) EP1265616B1 (hu)
JP (1) JP2003527416A (hu)
KR (1) KR100805648B1 (hu)
CN (1) CN1239160C (hu)
AR (1) AR031563A1 (hu)
AT (1) ATE326227T1 (hu)
AU (2) AU5003401A (hu)
BG (1) BG66075B1 (hu)
BR (1) BR0109334A (hu)
CA (1) CA2402983A1 (hu)
CY (1) CY1105632T1 (hu)
CZ (1) CZ20023162A3 (hu)
DE (1) DE60119703T2 (hu)
DK (1) DK1265616T3 (hu)
EA (1) EA005592B1 (hu)
EE (1) EE05129B1 (hu)
ES (1) ES2261393T3 (hu)
HK (1) HK1049449B (hu)
HR (1) HRP20020837B1 (hu)
HU (1) HUP0302093A3 (hu)
IL (1) IL151512A0 (hu)
MX (1) MXPA02009116A (hu)
NO (1) NO326886B1 (hu)
NZ (1) NZ521171A (hu)
PL (1) PL201762B1 (hu)
PT (1) PT1265616E (hu)
SK (1) SK286169B6 (hu)
TW (1) TWI271194B (hu)
WO (1) WO2001070208A2 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
IL157944A0 (en) * 2001-03-16 2004-03-28 Wyeth Corp Hormone replacement therapy
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
US20030216366A1 (en) * 2002-04-03 2003-11-20 Leonard Thomas W. Step-down estrogen therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
EP1509215B1 (en) * 2002-06-06 2006-11-02 Hormos Medical Ltd. Treatment or prevention of urogenital atrophy and its symptoms in women
CA2489847A1 (en) * 2002-06-25 2003-12-31 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
RU2005101635A (ru) * 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
US8349819B2 (en) 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
JP2009521533A (ja) 2005-12-27 2009-06-04 デュラメド ファーマシューティカルズ インコーポレーティッド 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法
RU2008136024A (ru) * 2006-04-05 2010-05-10 Вайет (Us) Способы предотвращения и лечения состояний, возникающих в результате местного дефицита эстрогенов
PE20081301A1 (es) * 2006-11-29 2008-10-01 Wyeth Corp Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
EP2121553B1 (en) * 2007-02-14 2012-06-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US9734496B2 (en) 2009-05-29 2017-08-15 Paypal, Inc. Trusted remote attestation agent (TRAA)
ES2773079T3 (es) * 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015089489A1 (en) * 2013-12-13 2015-06-18 Requis Pharmaceuticals Inc. Antihistamines in combination with a range of substance for improved health
EP3137087B1 (en) 2014-04-28 2023-09-06 The Regents of the University of California Estrogen combination for treatment of multiple sclerosis
EP3137088B1 (en) 2014-04-28 2023-08-30 The Regents of The University of California Pharmaceutical packaging for estriol therapy for the treatment of multiple sclerosis
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016036719A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
ES2957543T3 (es) 2014-09-29 2024-01-22 Univ California Composiciones y métodos para mantener la función cognitiva
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20210386757A1 (en) * 2018-10-17 2021-12-16 Sarah S. Stadler Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
NO301689B1 (no) * 1987-09-24 1997-12-01 Jencap Research Ltd Kontraseptivt preparat i form av en forpakning
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
EP1265616B1 (en) 2006-05-17
HK1049449B (zh) 2006-07-28
AU5003401A (en) 2001-10-03
CN1418102A (zh) 2003-05-14
CA2402983A1 (en) 2001-09-27
CY1105632T1 (el) 2010-12-22
HK1049449A1 (en) 2003-05-16
DE60119703T2 (de) 2006-10-19
NO20024478L (no) 2002-09-19
PT1265616E (pt) 2006-08-31
EA005592B1 (ru) 2005-04-28
HUP0302093A2 (hu) 2003-10-28
BG66075B1 (en) 2011-02-28
IL151512A0 (en) 2003-04-10
WO2001070208A3 (en) 2002-04-25
EP1265616A2 (en) 2002-12-18
KR100805648B1 (ko) 2008-02-26
BG107095A (bg) 2003-05-30
SK286169B6 (sk) 2008-04-07
AR031563A1 (es) 2003-09-24
AU2001250034B2 (en) 2005-03-24
DK1265616T3 (da) 2006-06-12
PL363157A1 (en) 2004-11-15
EE200200535A (et) 2004-04-15
CZ20023162A3 (cs) 2003-03-12
NO20024478D0 (no) 2002-09-19
NO326886B1 (no) 2009-03-16
BR0109334A (pt) 2002-12-24
CN1239160C (zh) 2006-02-01
WO2001070208A2 (en) 2001-09-27
EA200201000A1 (ru) 2003-02-27
US20010034340A1 (en) 2001-10-25
EE05129B1 (et) 2009-02-16
PL201762B1 (pl) 2009-05-29
ATE326227T1 (de) 2006-06-15
TWI271194B (en) 2007-01-21
SK13482002A3 (sk) 2003-02-04
KR20020084230A (ko) 2002-11-04
MXPA02009116A (es) 2003-03-12
JP2003527416A (ja) 2003-09-16
HRP20020837A2 (en) 2004-02-29
ES2261393T3 (es) 2006-11-16
US20090005351A1 (en) 2009-01-01
NZ521171A (en) 2004-09-24
DE60119703D1 (de) 2006-06-22
HRP20020837B1 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
HUP0302093A3 (en) Use of conjugated estrogens and medroxyprogesterone acetate for producing pharmaceutical compositions for hormone replacement therapy
HUP0204291A3 (en) Use of composition containing estrogen and drospirenone for hormone replacement therapy
HUP0101693A3 (en) Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
HUP0301422A3 (en) Pharmaceutical compositions of estrogenic agents
HUP0103494A3 (en) Process for intermittent administration use of growth hormone secretagogues for the manufacture of pharmaceutical compositions for intermittent administration and kit comprising thereof
ZA200605224B (en) Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
AU4541701A (en) Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
HUP0102913A3 (en) Use of biogenic estrogen sulfamates for producing pharmaceutical compositions for hormone replacement therapy
HRP20020893A2 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0301317A3 (en) Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions
HUP0300626A3 (en) Use of progestogen and mifepristone for preparation of anticancer pharmaceutical compositions
HUP0202741A3 (en) Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
HUP0201956A2 (en) Formulations of steroid solutions for inhalatory administration and process for their preparation
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
HUP0301134A3 (en) Use of 7-hydroxyepiandrosterone having neuroprotective activity for preparing pharmaceutical compositions
AU4825200A (en) Oral steroidal hormone compositions and methods of use
SI1265616T1 (sl) Hormonsko nadomestno zdravljenje z uporabo kombinacije konjugiranih estrogenov in medroksiprogesteron-acetata
HUP0204336A3 (en) Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use and pharmaceutical compositions containing them their
HUP0201875A3 (en) Use of antiprogestagens for preparing pharmaceutical compositions for contraception in combined therapy
HUP0400440A2 (en) Pharmaceutical composition for nasal delivery of estradiol and norethisterone

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees